<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Biochem Nutr</journal-id><journal-id journal-id-type="publisher-id">JCBN</journal-id><journal-title>Journal of Clinical Biochemistry and Nutrition</journal-title><issn pub-type="ppub">0912-0009</issn><issn pub-type="epub">1880-5086</issn><publisher><publisher-name>the Society for Free Radical Research Japan</publisher-name><publisher-loc>Kyoto, Japan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19015757</article-id><article-id pub-id-type="pmc">2581757</article-id><article-id pub-id-type="publisher-id">jcbn2008067</article-id><article-id pub-id-type="doi">10.3164/jcbn.2008067</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Role of Vitamins C and E in Regulating Antioxidant and Pro-Oxidant Markers in Preeclampsia</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Suhail</surname><given-names>Mohd</given-names></name><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Faizul Suhail</surname><given-names>Mohd</given-names></name></contrib><contrib contrib-type="author"><name><surname>Khan</surname><given-names>Hina</given-names></name></contrib></contrib-group><aff id="aff1">City Nursing and Maternity Home Research Center, 21 Minhajpur, Allahabad-211003, India</aff><author-notes><corresp id="cor1">*To whom correspondence should be addressed.   Tel &amp; Fax: +91-532-2401475   E-mail: <email>profmsuhail@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2008</year></pub-date><pub-date pub-type="epub"><day>31</day><month>10</month><year>2008</year></pub-date><volume>43</volume><issue>3</issue><fpage>210</fpage><lpage>220</lpage><history><date date-type="received"><day>5</day><month>3</month><year>2008</year></date><date date-type="accepted"><day>23</day><month>6</month><year>2008</year></date></history><permissions><copyright-statement>Copyright © 2008 JCBN</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access"><p>This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p><offsets xml_i="2646" xml_f="3740" txt_i="11" txt_f="1105">We compared three groups of pregnant women: placebo with normotensive women, group A which included preeclamptics, and group B which comprised preeclamptics who were supplemented their diets with vitamins C and E. MDA increased from 6.22 ± 2.8 (placebo) to 8.48 ± 1.2 (A) and 8.02 ± 1.8 nmol/gHb (B). NO concentrations were enhanced from 19.3 ± 4.2 (P) to 23.8 ± 6.4 (A) and 24.1 ± 5.4 µmol/L (B). GSH contents were decreased from 10.42 ± 2.81 (P) to 8.02 ± 2.92 (A) and 9.39 ± 1.02 µmol/g Hb (B), whereas GSSG concentrations increased from 0.98 ± 0.28 (P) to 1.24 ± 0.29 (A) and 1.08 ± 0.12 µmol/g Hb (B). SOD activity decreased 23% in A and 14% in B; GRx decreased 27% in A and 5.5% in B; GPx decreased 12% in A and 9.6% in B. Catalase activity, however, increased 27% in A and 29% in B as compared to control. Thus, we conclude that the use of vitamins C and E should be considered for the control of certain important biochemical indices during the development of preeclampsia; however, further studies are needed to develop methods for the prevention of preeclampsia in women at high risk.</offsets></p></abstract><kwd-group><kwd>vitamin C &amp; E</kwd><kwd>antioxidants &amp; pro-oxidants</kwd><kwd>enzymatic &amp; non-enzymatic</kwd><kwd>preeclampsia</kwd></kwd-group></article-meta></front><body><sec sec-type="introduction"><title><offsets xml_i="3976" xml_f="3988" txt_i="1113" txt_f="1125">Introduction</offsets></title><p><offsets xml_i="3999" xml_f="4378" txt_i="1126" txt_f="1505">Preeclampsia is a disorder of pregnancy characterized by pregnancy-induced hypertension (≥140 mmHg systolic and/or ≥90 mmHg diastolic blood pressure), new-onset proteinuria (≥300 mg protein/day), and edema occurring in the second half of pregnancy. A significant reduction in the incidence of preeclampsia was found in women at risk who were taking vitamins C and E supplements [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="4409" xml_f="4410" txt_i="1505" txt_f="1506">1</offsets></xref><offsets xml_i="4417" xml_f="4561" txt_i="1506" txt_f="1650">]. Antioxidant supplements in these women were also shown to be associated with changes in indices of oxidative stress and placental functions [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="4592" xml_f="4593" txt_i="1650" txt_f="1651">2</offsets></xref><offsets xml_i="4600" xml_f="4700" txt_i="1651" txt_f="1751">]. The vitamin C content in both mild and severe preeclamptics was found to decrease significantly [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="4731" xml_f="4732" txt_i="1751" txt_f="1752">3</offsets></xref><offsets xml_i="4739" xml_f="4784" txt_i="1752" txt_f="1797">] in association with enhanced peroxidation [</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="4815" xml_f="4816" txt_i="1797" txt_f="1798">4</offsets></xref><offsets xml_i="4823" xml_f="4851" txt_i="1798" txt_f="1826">] and lowered thiol levels [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="4882" xml_f="4883" txt_i="1826" txt_f="1827">5</offsets></xref><offsets xml_i="4890" xml_f="5083" txt_i="1827" txt_f="2020">]. The reason for the decrease in plasma ascorbate is not very clear, but it is consistent with the hypothesis that uteroplacental perfusion induces oxidative stress and ascorbate consumption [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="5114" xml_f="5115" txt_i="2020" txt_f="2021">6</offsets></xref><offsets xml_i="5122" xml_f="5404" txt_i="2021" txt_f="2303">]. The functional consequence and the possible role of the decrease in plasma vitamin C reserves in preeclampsia (PE) are consistent with the fact that women who ingested less vitamin C than the recommended daily allowance (8.5 mg) were at a 2-fold increased risk of developing PE [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="5435" xml_f="5436" txt_i="2303" txt_f="2304">7</offsets></xref><offsets xml_i="5443" xml_f="5619" txt_i="2304" txt_f="2480">]. Currently, there are several large multicenter trials in progress to determine the efficacy of antioxidant therapy in the prevention of preeclampsia. Some negative results [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="5650" xml_f="5651" txt_i="2480" txt_f="2481">8</offsets></xref><offsets xml_i="5658" xml_f="6133" txt_i="2481" txt_f="2956">] have appeared but more results are awaited finally with interest and will determine whether antioxidants are effective in preventing preeclampsia in all populations, or whether such therapy will be population specific. However, in a recent review, antioxidant therapy has been suggested and that the prophylactic supplementation of vitamins C and E to pregnant women is associated with reduced incidence of preeclampsia and decreased placental and endothelial dysfunction [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="6164" xml_f="6165" txt_i="2956" txt_f="2957">9</offsets></xref><offsets xml_i="6172" xml_f="6174" txt_i="2957" txt_f="2959">].</offsets></p><p><offsets xml_i="6181" xml_f="6285" txt_i="2960" txt_f="3064">In preeclampsia, an inverse correlation between vitamin E levels and lipid peroxidation has been found [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="6317" xml_f="6319" txt_i="3064" txt_f="3066">10</offsets></xref><offsets xml_i="6326" xml_f="6450" txt_i="3066" txt_f="3190">] suggesting that vitamin E content in plasma may be used as a prognostic marker of the likely development of preeclampsia [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="6482" xml_f="6484" txt_i="3190" txt_f="3192">11</offsets></xref><offsets xml_i="6491" xml_f="6654" txt_i="3192" txt_f="3355">]. In addition, there was a relationship found between the extent of vitamin E deficiency and increased lipid peroxidation with enhanced diastolic blood pressure [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="6686" xml_f="6688" txt_i="3355" txt_f="3357">12</offsets></xref><offsets xml_i="6695" xml_f="6935" txt_i="3357" txt_f="3597">]. Thus, decreased plasma levels of vitamin E could be a contributory factor of hypertension in preeclampsia, but other studies have not demonstrated significant differences in plasma vitamin E levels between normal and preeclamptic women [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="6967" xml_f="6969" txt_i="3597" txt_f="3599">13</offsets></xref><offsets xml_i="6976" xml_f="7192" txt_i="3599" txt_f="3815">]. Moreover, some results are at variance with the prevailing opinion, since increased plasma levels of vitamin E among women with preeclampsia as compared to those in normotensive pregnant women have been reported [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="7224" xml_f="7226" txt_i="3815" txt_f="3817">14</offsets></xref><offsets xml_i="7233" xml_f="7626" txt_i="3817" txt_f="4210">]. The latter study does not support the hypothesis of a causal relationship between decreased dietary vitamin E consumption and plasma levels and the development of preeclampsia. Thus, there is not a consensus whether or not these antioxidant vitamins exert a positive effect to control preeclamptic developments, especially as they pertain to oxidative stress, this area needs further study.</offsets></p><p><offsets xml_i="7633" xml_f="7974" txt_i="4211" txt_f="4552">During pregnancy, nitric oxide (NO) is one of the most important relaxing factors of myometrium and also no less important in the control of blood flow in uterus and placenta. Oxidative stress developed in preeclampsia may cause endothelial dysfunction, which may lead to hypertension by decreased release of vasodilating agents such as NO [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="8006" xml_f="8008" txt_i="4552" txt_f="4554">15</offsets></xref><offsets xml_i="8015" xml_f="8149" txt_i="4554" txt_f="4688">]. NO is a potent vasodilator, and its altered production by the vascular endothelium may influence the pathogenesis of preeclampsia [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="8181" xml_f="8183" txt_i="4688" txt_f="4690">16</offsets></xref><offsets xml_i="8190" xml_f="8245" txt_i="4690" txt_f="4745">]. NO regulates leukocyte adhesion to the endothelium [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="8277" xml_f="8279" txt_i="4745" txt_f="4747">17</offsets></xref><offsets xml_i="8286" xml_f="8369" txt_i="4747" txt_f="4830">] and inhibits vascular smooth muscle cell proliferation and platelet aggregation [</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="8401" xml_f="8403" txt_i="4830" txt_f="4832">18</offsets></xref><offsets xml_i="8410" xml_f="8412" txt_i="4832" txt_f="4834">].</offsets></p><p><offsets xml_i="8419" xml_f="8676" txt_i="4835" txt_f="5092">All these functions could be impaired by the consumption of NO by superoxide anions produced during oxidative stress, thereby diminishing NO bioavailability. Consistent with this are the findings of a diminished level of NO in plasma of preeclamptic women [</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="8708" xml_f="8710" txt_i="5092" txt_f="5094">19</offsets></xref><offsets xml_i="8717" xml_f="8842" txt_i="5094" txt_f="5219">]. The status of plasma NO in preeclampsia is, however, still controversial, and different groups have reported an increase [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="8874" xml_f="8876" txt_i="5219" txt_f="5221">20</offsets></xref><offsets xml_i="8883" xml_f="8885" txt_i="5221" txt_f="5223">, </offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="8917" xml_f="8919" txt_i="5223" txt_f="5225">21</offsets></xref><offsets xml_i="8926" xml_f="8941" txt_i="5225" txt_f="5240">], a decrease [</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="8973" xml_f="8975" txt_i="5240" txt_f="5242">22</offsets></xref><offsets xml_i="8982" xml_f="8984" txt_i="5242" txt_f="5244">, </offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="9016" xml_f="9018" txt_i="5244" txt_f="5246">23</offsets></xref><offsets xml_i="9025" xml_f="9041" txt_i="5246" txt_f="5262">] or no change [</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="9073" xml_f="9075" txt_i="5262" txt_f="5264">24</offsets></xref><offsets xml_i="9082" xml_f="9236" txt_i="5264" txt_f="5418">] in NOx levels (nitrites and nitrates, products of stable degradation of NO). A pathogenic link between serum uric acid is evident from several studies [</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="9268" xml_f="9270" txt_i="5418" txt_f="5420">25</offsets></xref><offsets xml_i="9277" xml_f="9279" txt_i="5420" txt_f="5422">, </offsets><xref ref-type="bibr" rid="B26"><offsets xml_i="9311" xml_f="9313" txt_i="5422" txt_f="5424">26</offsets></xref><offsets xml_i="9320" xml_f="9534" txt_i="5424" txt_f="5638">] although it has dual roles. It may have beneficial functions [acting as an antioxidant] as well as detrimental actions [to stimulate vascular smooth muscle cell proliferation and induce endothelial dysfunction] [</offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="9566" xml_f="9568" txt_i="5638" txt_f="5640">27</offsets></xref><offsets xml_i="9575" xml_f="9577" txt_i="5640" txt_f="5642">].</offsets><italic></italic><offsets xml_i="9594" xml_f="9747" txt_i="5642" txt_f="5795">Thus, our present study also aimed to evaluate NO and uric acid contents in the plasma of control and preeclamptics with and without vitamin supplements.</offsets></p><p><offsets xml_i="9754" xml_f="10240" txt_i="5796" txt_f="6282">There is no satisfactory treatment of this disease, except steps to avoid or reduce complications such as hypertension and eclamptic seizures and early delivery is the only successful treatment. It is hypothesized that preeclamptic condition could be explained by alterations in the function of vascular endothelium and placenta, likely in response to reduced perfusion, produces circulating factor(s) that alters endothelial function. These factor(s) are products of oxidative stress [</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="10272" xml_f="10274" txt_i="6282" txt_f="6284">28</offsets></xref><offsets xml_i="10281" xml_f="10336" txt_i="6284" txt_f="6339">] and placenta may be the site of the lipid peroxides [</offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="10368" xml_f="10370" txt_i="6339" txt_f="6341">29</offsets></xref><offsets xml_i="10377" xml_f="10772" txt_i="6341" txt_f="6736">]. The maternal circulating components were found to regulate oxidative status of glutathione redox cycle and adhesion molecule expression in endothelial cells (ECs). Reduced cellular glutathione, and glutathione reductase (GRx) activity and altered glutathione peroxidase (GPx) activity accompany increased inflammatory reactions in ECs responding to circulatory toxic factors in preeclampsia [</offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="10804" xml_f="10806" txt_i="6736" txt_f="6738">30</offsets></xref><offsets xml_i="10813" xml_f="10948" txt_i="6738" txt_f="6873">]. Various studies have highlighted the asymmetric alterations in the activities of superoxide dismutase (SOD), catalase, GRx and GPx [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="10979" xml_f="10980" txt_i="6873" txt_f="6874">5</offsets></xref><offsets xml_i="10987" xml_f="10989" txt_i="6874" txt_f="6876">, </offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="11021" xml_f="11023" txt_i="6876" txt_f="6878">30</offsets></xref><offsets xml_i="11030" xml_f="11032" txt_i="6878" txt_f="6880">, </offsets><xref ref-type="bibr" rid="B31"><offsets xml_i="11064" xml_f="11066" txt_i="6880" txt_f="6882">31</offsets></xref><offsets xml_i="11073" xml_f="11075" txt_i="6882" txt_f="6884">].</offsets></p><p><offsets xml_i="11082" xml_f="11492" txt_i="6885" txt_f="7295">In view of the contradictory reports and the seriousness of preeclampsia, the present study included the determination of the activities of catalase, SOD, GPx and GRx in the blood of normal and preeclamptic women with and without vitamin treatment, along-with the contents of MDA, GSH, GSSG, GSSG/GSH, NO and uric acid, to collectively evaluate the roles of vitamins C and E in the regulation of these factors.</offsets></p></sec><sec sec-type="materials|methods"><title><offsets xml_i="11543" xml_f="11564" txt_i="7297" txt_f="7318">Materials and Methods</offsets></title><sec><title><offsets xml_i="11584" xml_f="11593" txt_i="7319" txt_f="7328">Chemicals</offsets></title><p><offsets xml_i="11604" xml_f="11934" txt_i="7329" txt_f="7659">ATP, NADPH, GSH, GSSG, Aspergillus nitrate reductase, and GRx, EDTA, TBA and butylated hydroxytoluene (BHT) were obtained from Sigma Chemical Company (St. Louis, MO.). Other chemicals were obtained from E. Merck (Mumbai, India). All other reagents used were of analytical grade, either from BDH or SISCO Chemicals (Mumbai, India).</offsets></p></sec><sec><title><offsets xml_i="11956" xml_f="11964" txt_i="7661" txt_f="7669">Subjects</offsets></title><p><offsets xml_i="11975" xml_f="12600" txt_i="7670" txt_f="8295">In India, pregnant women are encouraged to book and to attend regular antenatal check ups. Standard antenatal care is defined as monthly visits up to 28 weeks; fortnightly until 34 weeks and weekly visits thereafter. The patients in our study included pregnant women with normal blood pressure, preeclamptic women admitted to our hospital who had been or not under regular care, and also those who were referred from private sectors or primary health centers. The control group (placebo) consisted of 20 normotensive pregnant women who were taking regular prenatal vitamins from the second trimester of pregnancy to delivery.</offsets></p><p><offsets xml_i="12607" xml_f="13515" txt_i="8296" txt_f="9204">Group A comprised 22 patients who were not taking any vitamin supplements, as they belonged to rural areas with incomes below the poverty-line; they were not booked cases and they arrived with full term pregnancies just a few days before delivery. Group B initially consisted of a high number of patients who were viewed as being at an increased risk of preeclampsia because of factors such as preeclampsia in a preceding pregnancy, HELLP syndrome, or eclampsia in any past pregnancy at any gestational stage, and who were taking additional vitamin supplement (1000 mg vitamin C plus 400 IU vitamin E per day) from the second trimester of pregnancy to delivery as mentioned for the controls (placebo). At a later stage, however, some of the women in this group did not appear at the time of full term delivery. For this group, 21 women who had developed severe preeclamptic conditions agreed to donate blood.</offsets></p><p><offsets xml_i="13522" xml_f="14266" txt_i="9205" txt_f="9949">The present study was carried out with the prior approval of the local ethical committee. All the patients mentioned above gave their consent in writing, and the objectives of the study were fully explained to them in detail prior to taking consent. They were always instructed to fast between 9 p.m. till retiring in the night before the blood collection. On the morning of the test they were requested to have only a light breakfast such as simple toast avoiding any cooked breakfast, meat, cereals, fruit juices and any nutritional supplements. They were advised to abstain from having coffee, chocolates, etc. for at least 2 h before coming for blood sampling; 8 ml of venous blood was collected in EDTA-treated tubes from the cubital vein.</offsets></p><p><offsets xml_i="14273" xml_f="14643" txt_i="9950" txt_f="10320">Clinical examination and history taking excluded women addicted to tobacco, patients with diabetes, ischemic heart disease, a history of stroke, kidney disorders or other conditions of known free radical etiology. The criteria for dividing women into normotensive and preeclamptic groups have been set at a blood pressure of 140/90 mmHg or higher, proteinuria and edema.</offsets></p></sec><sec><title><offsets xml_i="14665" xml_f="14742" txt_i="10322" txt_f="10399">Estimation of plasma levels of NO as stable metabolites (nitrite + nitrate) [</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="14774" xml_f="14776" txt_i="10399" txt_f="10401">21</offsets></xref><offsets xml_i="14783" xml_f="14784" txt_i="10401" txt_f="10402">]</offsets></title><p><offsets xml_i="14795" xml_f="14837" txt_i="10403" txt_f="10445">To 300 µl of plasma was added 300 µl of KH</offsets><sub><offsets xml_i="14842" xml_f="14843" txt_i="10445" txt_f="10446">2</offsets></sub><offsets xml_i="14849" xml_f="14851" txt_i="10446" txt_f="10448">PO</offsets><sub><offsets xml_i="14856" xml_f="14857" txt_i="10448" txt_f="10449">4</offsets></sub><offsets xml_i="14863" xml_f="14865" txt_i="10449" txt_f="10451">/K</offsets><sub><offsets xml_i="14870" xml_f="14871" txt_i="10451" txt_f="10452">2</offsets></sub><offsets xml_i="14877" xml_f="15090" txt_i="10452" txt_f="10665">HPO4 buffer (pH 7.5), 50 µl of 2 mM NADPH, 50 µl of 50 µM FAD and 50 µl of I unit/ml aspergillus nitrate reductase. This was incubated at room temperature for one hour followed by the addition of 500 µl of 0.2 M Z</offsets><sub><offsets xml_i="15095" xml_f="15096" txt_i="10665" txt_f="10666">n</offsets></sub><offsets xml_i="15102" xml_f="15104" txt_i="10666" txt_f="10668">SO</offsets><sub><offsets xml_i="15109" xml_f="15110" txt_i="10668" txt_f="10669">4</offsets></sub><offsets xml_i="15116" xml_f="15527" txt_i="10669" txt_f="11080"> and 70 µl of 2 M NaOH to deproteinize the sample. After centrifugation, 0.75 ml of the supernatant was added to 1 ml of 1% sulphanilic acid (in 4 M HCl). After 10 min at room temperature, 0.75 ml of freshly prepared 1% N-naphthyl ethylene diamine was also added. The resultant color developed was measured at 548 nm using spectrophotometer. Nitrite concentration was calculated using nitrite standard solution.</offsets></p></sec><sec><title><offsets xml_i="15549" xml_f="15571" txt_i="11082" txt_f="11104">Uric acid estimation [</offsets><xref ref-type="bibr" rid="B32"><offsets xml_i="15603" xml_f="15605" txt_i="11104" txt_f="11106">32</offsets></xref><offsets xml_i="15612" xml_f="15613" txt_i="11106" txt_f="11107">]</offsets></title><p><offsets xml_i="15624" xml_f="16066" txt_i="11108" txt_f="11550">Simple colorimetric method was employed. To 4 ml. N/23 sulphuric acid, 0.5 ml. serum was added and mixed. 0.5 ml. 5.6 % sodium tungstate was then added, mixed, and centrifuged. 3 ml of the decanted supernatant was placed in a test tube, to which was added 0.2 ml PTR (Phosphotungstic acid reaction reagent), mixed well, followed by the addition of 1.0 ml 0.6 N sodium hydroxide. Reading was taken after 15 min, at 720 nm on spectrophotometer.</offsets></p></sec><sec><title><offsets xml_i="16088" xml_f="16139" txt_i="11552" txt_f="11603">Isolation of erythrocyte and hemolysate preparation</offsets></title><p><offsets xml_i="16150" xml_f="16439" txt_i="11604" txt_f="11893">The blood samples were centrifuged at 1000 g for 15 min at 4°C and the isolated red cells were washed 4–5 times with 0.154 M NaCl to remove plasma and buffy coat. After the final wash, the required packed cells were lysed by hypotonic shock and different dilutions were used as hemolysate.</offsets></p></sec><sec><title><offsets xml_i="16461" xml_f="16484" txt_i="11895" txt_f="11918">Hemoglobin estimation [</offsets><xref ref-type="bibr" rid="B33"><offsets xml_i="16516" xml_f="16518" txt_i="11918" txt_f="11920">33</offsets></xref><offsets xml_i="16525" xml_f="16526" txt_i="11920" txt_f="11921">]</offsets></title><p><offsets xml_i="16537" xml_f="16547" txt_i="11922" txt_f="11932">Hemoglobin</offsets><italic></italic><offsets xml_i="16564" xml_f="16635" txt_i="11932" txt_f="12003">content of the erythrocyte was measured using cyanmethemoglobin method.</offsets></p></sec><sec><title><offsets xml_i="16657" xml_f="16701" txt_i="12005" txt_f="12049">Determination of reduced glutathione (GSH) [</offsets><xref ref-type="bibr" rid="B34"><offsets xml_i="16733" xml_f="16735" txt_i="12049" txt_f="12051">34</offsets></xref><offsets xml_i="16742" xml_f="16743" txt_i="12051" txt_f="12052">]</offsets></title><p><offsets xml_i="16754" xml_f="17023" txt_i="12053" txt_f="12322">Packed red cells (0.2 ml) were used in the assay. The GSH was made to react with 5'5-dithiobis (2-nitrobenzoic acid) [DTNB], which reacts with sulfhydryl groups, to develop a stable color. The absorbance was measured at 412 nm and GSH content was expressed as µmol/gHb.</offsets></p></sec><sec><title><offsets xml_i="17045" xml_f="17090" txt_i="12324" txt_f="12369">Quantitation of oxidized glutathione (GSSG) [</offsets><xref ref-type="bibr" rid="B35"><offsets xml_i="17122" xml_f="17124" txt_i="12369" txt_f="12371">35</offsets></xref><offsets xml_i="17131" xml_f="17132" txt_i="12371" txt_f="12372">]</offsets></title><p><offsets xml_i="17143" xml_f="17196" txt_i="12373" txt_f="12426">Erythrocytes lysate was deproteinized with 0.5 M HClO</offsets><sub><offsets xml_i="17201" xml_f="17202" txt_i="12426" txt_f="12427">4</offsets></sub><offsets xml_i="17208" xml_f="17459" txt_i="12427" txt_f="12678">. Then estimation was made on the basis of reduction of GSSG in presence of NADPH and GRx and decrease of NADPH at 340 nm after initiating the reaction by adding GRx was taken as an index of GSSG content, which was evaluated and expressed as µmol/gHb.</offsets></p></sec><sec><title><offsets xml_i="17481" xml_f="17515" txt_i="12680" txt_f="12714">Estimation of lipid peroxidation [</offsets><xref ref-type="bibr" rid="B36"><offsets xml_i="17547" xml_f="17549" txt_i="12714" txt_f="12716">36</offsets></xref><offsets xml_i="17556" xml_f="17557" txt_i="12716" txt_f="12717">]</offsets></title><p><offsets xml_i="17568" xml_f="18244" txt_i="12718" txt_f="13394">Packed red cells (0.2 ml) were used for the quantitation of malondialdehyde (MDA) as thiobarbituric acid reactive substances (TBARS). Aliquots of 0.2 ml were mixed thoroughly with 0.8 ml of phosphate buffered saline (pH 7.4) and 25 µl of butylatedhydroxytoulene solution. After adding 0.5 ml of 30% trichloroacetic acid, the samples were placed on ice-bath for 2 h and then centrifuged at 2000 × g at 25°C for 15 min. One ml of supernatant was mixed with 75 µl of 0.1 M EDTA and 250 µl of 1% thiobarbituric acid in 0.05 M NaOH and placed on boiling water for 15 min. After cooling to room temperature, absorbance was measured at 532 nm. MDA contents are expressed as nmol/gHb.</offsets></p></sec><sec><title><offsets xml_i="18266" xml_f="18289" txt_i="13396" txt_f="13419">Assay of GPx activity [</offsets><xref ref-type="bibr" rid="B37"><offsets xml_i="18321" xml_f="18323" txt_i="13419" txt_f="13421">37</offsets></xref><offsets xml_i="18330" xml_f="18331" txt_i="13421" txt_f="13422">]</offsets></title><p><offsets xml_i="18342" xml_f="18514" txt_i="13423" txt_f="13595">GPx activity was measured spectrophotometrically at 340 nm in 50 mM phosphate, 5 mM EDTA, pH 7.0 containing 0.3 mM NADPH, 0.3 U/ml GRx, 5 mM GSH, 4 mM sodium azide, 75 µM H</offsets><sub><offsets xml_i="18519" xml_f="18520" txt_i="13595" txt_f="13596">2</offsets></sub><offsets xml_i="18526" xml_f="18527" txt_i="13596" txt_f="13597">O</offsets><sub><offsets xml_i="18532" xml_f="18533" txt_i="13597" txt_f="13598">2</offsets></sub><offsets xml_i="18539" xml_f="18728" txt_i="13598" txt_f="13787"> and 10 µl of erythrocyte lysate in a final reaction mixture of 3 ml. One unit of GPx was considered to be the amount necessary to oxidize 1 µmol NADPH/min. Activity was expressed as U/gHb.</offsets></p></sec><sec><title><offsets xml_i="18750" xml_f="18773" txt_i="13789" txt_f="13812">Assay of SOD activity [</offsets><xref ref-type="bibr" rid="B34"><offsets xml_i="18805" xml_f="18807" txt_i="13812" txt_f="13814">34</offsets></xref><offsets xml_i="18814" xml_f="18815" txt_i="13814" txt_f="13815">]</offsets></title><p><offsets xml_i="18826" xml_f="19084" txt_i="13816" txt_f="14074">The assay mixture contained 1M Tris, 5 mM EDTA buffer, pH 8.0, and 10 mM pyrogallol and the inhibition of pyrogallol oxidation by SOD was monitored at 420 nm, and the amount of enzyme producing 50% inhibition was taken as one unit of enzyme activity (U/gHb).</offsets></p></sec><sec><title><offsets xml_i="19106" xml_f="19134" txt_i="14076" txt_f="14104">Assay of catalase activity [</offsets><xref ref-type="bibr" rid="B38"><offsets xml_i="19166" xml_f="19168" txt_i="14104" txt_f="14106">38</offsets></xref><offsets xml_i="19175" xml_f="19176" txt_i="14106" txt_f="14107">]</offsets></title><p><offsets xml_i="19187" xml_f="19281" txt_i="14108" txt_f="14202">The assay mixture contained 1 M Tris, 5 mM EDTA buffer, pH 7.0 and 200 mM hydrogen peroxide (H</offsets><sub><offsets xml_i="19286" xml_f="19287" txt_i="14202" txt_f="14203">2</offsets></sub><offsets xml_i="19293" xml_f="19294" txt_i="14203" txt_f="14204">O</offsets><sub><offsets xml_i="19299" xml_f="19300" txt_i="14204" txt_f="14205">2</offsets></sub><offsets xml_i="19306" xml_f="19327" txt_i="14205" txt_f="14226">). Disappearance of H</offsets><sub><offsets xml_i="19332" xml_f="19333" txt_i="14226" txt_f="14227">2</offsets></sub><offsets xml_i="19339" xml_f="19340" txt_i="14227" txt_f="14228">O</offsets><sub><offsets xml_i="19345" xml_f="19346" txt_i="14228" txt_f="14229">2</offsets></sub><offsets xml_i="19352" xml_f="19453" txt_i="14229" txt_f="14330"> was monitored at 240 nm for 30 s and the activity of catalase was evaluated and expressed as kU/gHb.</offsets></p></sec><sec><title><offsets xml_i="19475" xml_f="19498" txt_i="14332" txt_f="14355">Assay of GRx activity [</offsets><xref ref-type="bibr" rid="B39"><offsets xml_i="19530" xml_f="19532" txt_i="14355" txt_f="14357">39</offsets></xref><offsets xml_i="19539" xml_f="19540" txt_i="14357" txt_f="14358">]</offsets></title><p><offsets xml_i="19551" xml_f="19605" txt_i="14359" txt_f="14413">The main reagent was prepared by combining 18 ml of KH</offsets><sub><offsets xml_i="19610" xml_f="19611" txt_i="14413" txt_f="14414">2</offsets></sub><offsets xml_i="19617" xml_f="19619" txt_i="14414" txt_f="14416">PO</offsets><sub><offsets xml_i="19624" xml_f="19625" txt_i="14416" txt_f="14417">4</offsets></sub><offsets xml_i="19631" xml_f="19744" txt_i="14417" txt_f="14530"> buffer 139 mM, 0.76 mM EDTA, pH 7.4 and 2 ml of NADPH 2.5 mM. The sample (20 µl of 1:20 hemolysate + 20 µl of KH</offsets><sub><offsets xml_i="19749" xml_f="19750" txt_i="14530" txt_f="14531">2</offsets></sub><offsets xml_i="19756" xml_f="19758" txt_i="14531" txt_f="14533">PO</offsets><sub><offsets xml_i="19763" xml_f="19764" txt_i="14533" txt_f="14534">4</offsets></sub><offsets xml_i="19770" xml_f="19845" txt_i="14534" txt_f="14609"> buffer), 220 µl of the main reagent and 5 µl of FAD 0.315 mM + 10 µl of KH</offsets><sub><offsets xml_i="19850" xml_f="19851" txt_i="14609" txt_f="14610">2</offsets></sub><offsets xml_i="19857" xml_f="19859" txt_i="14610" txt_f="14612">PO</offsets><sub><offsets xml_i="19864" xml_f="19865" txt_i="14612" txt_f="14613">4</offsets></sub><offsets xml_i="19871" xml_f="20006" txt_i="14613" txt_f="14748"> buffer were added to the cuvette and the absorbance at 340 nm was monitored for 200 s (step A). Then 30 µl of GSSG 22 mM + 10 µl of KH</offsets><sub><offsets xml_i="20011" xml_f="20012" txt_i="14748" txt_f="14749">2</offsets></sub><offsets xml_i="20018" xml_f="20020" txt_i="14749" txt_f="14751">PO</offsets><sub><offsets xml_i="20025" xml_f="20026" txt_i="14751" txt_f="14752">4</offsets></sub><offsets xml_i="20032" xml_f="20365" txt_i="14752" txt_f="15085"> buffer were added to start the reaction and the absorbance was followed for 175 s (step B). The final reaction volume was 315 µl. The difference in absorbance per minute between steps B and A was used to calculate the enzyme activity. The unit in µmol of NADPH oxidized/min and the GRx activity was evaluated and expressed as U/gHb.</offsets></p></sec><sec><title><offsets xml_i="20387" xml_f="20407" txt_i="15087" txt_f="15107">Statistical analysis</offsets></title><p><offsets xml_i="20418" xml_f="20495" txt_i="15108" txt_f="15185">Data were analyzed between placebo-P; and Group A and Group B by the Student </offsets><italic><offsets xml_i="20503" xml_f="20504" txt_i="15185" txt_f="15186">t</offsets></italic><offsets xml_i="20513" xml_f="20590" txt_i="15186" txt_f="15263">-test. The data were expressed as mean ± Standard Deviation. The statistical </offsets><italic><offsets xml_i="20598" xml_f="20599" txt_i="15263" txt_f="15264">t</offsets></italic><offsets xml_i="20608" xml_f="20648" txt_i="15264" txt_f="15304">-test was considered significant with a </offsets><italic><offsets xml_i="20656" xml_f="20657" txt_i="15304" txt_f="15305">p</offsets></italic><offsets xml_i="20666" xml_f="20734" txt_i="15305" txt_f="15373">-value of 0.05 or less. Calculations of the two-tailed probability: </offsets><italic><offsets xml_i="20742" xml_f="20743" txt_i="15373" txt_f="15374">p</offsets></italic><offsets xml_i="20752" xml_f="20764" txt_i="15374" txt_f="15386">-values and </offsets><italic><offsets xml_i="20772" xml_f="20775" txt_i="15386" txt_f="15389">SEM</offsets></italic><offsets xml_i="20784" xml_f="20861" txt_i="15389" txt_f="15466"> (Standard Error of Means) were performed using GraphPad QuickCalcs Software.</offsets></p></sec></sec><sec sec-type="results"><title><offsets xml_i="20908" xml_f="20915" txt_i="15469" txt_f="15476">Results</offsets></title><p><offsets xml_i="20926" xml_f="21098" txt_i="15477" txt_f="15649">The systolic and diastolic blood pressures of patients with preeclampsia who were taking or not taking vitamin supplements were higher (statistically extremely significant </offsets><italic><offsets xml_i="21106" xml_f="21107" txt_i="15649" txt_f="15650">p</offsets></italic><offsets xml_i="21116" xml_f="21435" txt_i="15650" txt_f="15962">&lt;0.0001) than those of normotensive patients. This indicates that the preeclampsia in both the cases was of severe nature. The preeclamptics presented with proteinuria &amp; edema, but differences in their average pulse rate were not significant. The demographic and clinical data of these groups are shown in Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="21467" xml_f="21468" txt_i="15962" txt_f="15963">1</offsets></xref><offsets xml_i="21475" xml_f="21476" txt_i="15963" txt_f="15964">.</offsets></p><sec><title><offsets xml_i="21492" xml_f="21513" txt_i="15965" txt_f="15986">NO, MDA, NO/MDA ratio</offsets></title><p><offsets xml_i="21524" xml_f="21701" txt_i="15987" txt_f="16164">Plasma lipid peroxides (MDA) levels were found to be elevated in preeclamptics with and without vitamin supplements. Moreover, the increase was significantly higher in Group A (</offsets><italic><offsets xml_i="21709" xml_f="21710" txt_i="16164" txt_f="16165">p</offsets></italic><offsets xml_i="21719" xml_f="21747" txt_i="16165" txt_f="16193"> = 0.0013) than in Group B (</offsets><italic><offsets xml_i="21755" xml_f="21756" txt_i="16193" txt_f="16194">p</offsets></italic><offsets xml_i="21765" xml_f="21807" txt_i="16194" txt_f="16236"> = 0.0184) as compared to placebo-P (Fig. </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="21837" xml_f="21838" txt_i="16236" txt_f="16237">1</offsets></xref><offsets xml_i="21845" xml_f="22015" txt_i="16237" txt_f="16407">). The nitric oxide contents were also observed to be at higher levels in preeclamptic women, but, in this case, the elevation was higher in Group B (highly significant, </offsets><italic><offsets xml_i="22023" xml_f="22024" txt_i="16407" txt_f="16408">p</offsets></italic><offsets xml_i="22033" xml_f="22073" txt_i="16408" txt_f="16448"> = 0.003) than in group A (significant, </offsets><italic><offsets xml_i="22081" xml_f="22082" txt_i="16448" txt_f="16449">p</offsets></italic><offsets xml_i="22091" xml_f="22122" txt_i="16449" txt_f="16480"> = 0.0111) as depicted in Fig. </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="22152" xml_f="22153" txt_i="16480" txt_f="16481">2</offsets></xref><offsets xml_i="22160" xml_f="22252" txt_i="16481" txt_f="16573">. The NO/MDA ratios, however, were not significantly different in all the three cases (Fig. </offsets><xref ref-type="fig" rid="F3"><offsets xml_i="22282" xml_f="22283" txt_i="16573" txt_f="16574">3</offsets></xref><offsets xml_i="22290" xml_f="22292" txt_i="16574" txt_f="16576">).</offsets></p></sec><sec><title><offsets xml_i="22314" xml_f="22356" txt_i="16578" txt_f="16620">GSH, GSSG, GSSG/GSH and uric acid contents</offsets></title><p><offsets xml_i="22367" xml_f="22424" txt_i="16621" txt_f="16678">The amount of reduced glutathione was found to decrease (</offsets><italic><offsets xml_i="22432" xml_f="22433" txt_i="16678" txt_f="16679">p</offsets></italic><offsets xml_i="22442" xml_f="22656" txt_i="16679" txt_f="16893"> = 0.0099, highly significant) during the development of preeclamptic conditions. But, this decrease was lesser in Group B with vitamin supplements. The fall in glutathione levels is statistically non-significant (</offsets><italic><offsets xml_i="22664" xml_f="22665" txt_i="16893" txt_f="16894">p</offsets></italic><offsets xml_i="22674" xml_f="22773" txt_i="16894" txt_f="16993"> = 0.1233) in Group B when compared to placebo, however comparison of A with B showed significant (</offsets><italic><offsets xml_i="22781" xml_f="22782" txt_i="16993" txt_f="16994">p</offsets></italic><offsets xml_i="22791" xml_f="22819" txt_i="16994" txt_f="17022"> = 0.0485) difference (Fig. </offsets><xref ref-type="fig" rid="F4"><offsets xml_i="22849" xml_f="22850" txt_i="17022" txt_f="17023">4</offsets></xref><offsets xml_i="22857" xml_f="22893" txt_i="17023" txt_f="17059">). Oxidized glutathione was higher (</offsets><italic><offsets xml_i="22901" xml_f="22902" txt_i="17059" txt_f="17060">p</offsets></italic><offsets xml_i="22911" xml_f="22992" txt_i="17060" txt_f="17141"> = 0.0053, highly significant) in Group A but this increase was not significant (</offsets><italic><offsets xml_i="23000" xml_f="23001" txt_i="17141" txt_f="17142">p</offsets></italic><offsets xml_i="23010" xml_f="23038" txt_i="17142" txt_f="17170"> = 0.1419) in Group B (Fig. </offsets><xref ref-type="fig" rid="F5"><offsets xml_i="23068" xml_f="23069" txt_i="17170" txt_f="17171">5</offsets></xref><offsets xml_i="23076" xml_f="23159" txt_i="17171" txt_f="17254">). The ratios of GSSG/GSH were also evaluated which gave interesting results (Fig. </offsets><xref ref-type="fig" rid="F6"><offsets xml_i="23189" xml_f="23190" txt_i="17254" txt_f="17255">6</offsets></xref><offsets xml_i="23197" xml_f="23242" txt_i="17255" txt_f="17300">). The ratio increase was higher in Group A (</offsets><italic><offsets xml_i="23250" xml_f="23251" txt_i="17300" txt_f="17301">p</offsets></italic><offsets xml_i="23260" xml_f="23319" txt_i="17301" txt_f="17360"> = 0.003, highly significant), but it was not significant (</offsets><italic><offsets xml_i="23327" xml_f="23328" txt_i="17360" txt_f="17361">p</offsets></italic><offsets xml_i="23337" xml_f="23436" txt_i="17361" txt_f="17460"> = 0.3483) in Group B. When groups A and B were compared, however, the difference was significant (</offsets><italic><offsets xml_i="23444" xml_f="23445" txt_i="17460" txt_f="17461">p</offsets></italic><offsets xml_i="23454" xml_f="23532" txt_i="17461" txt_f="17539"> = 0.0134). Uric acid contents were found to increase (extremely significant, </offsets><italic><offsets xml_i="23540" xml_f="23541" txt_i="17539" txt_f="17540">p</offsets></italic><offsets xml_i="23550" xml_f="23651" txt_i="17540" txt_f="17638">&lt;0.0001) both in Groups A and B as compared to placebo. But there was not significant difference (</offsets><italic><offsets xml_i="23659" xml_f="23660" txt_i="17638" txt_f="17639">p</offsets></italic><offsets xml_i="23669" xml_f="23724" txt_i="17639" txt_f="17694"> = 0.1813) between Groups A and B as evident from Fig. </offsets><xref ref-type="fig" rid="F7"><offsets xml_i="23754" xml_f="23755" txt_i="17694" txt_f="17695">7</offsets></xref><offsets xml_i="23762" xml_f="23763" txt_i="17695" txt_f="17696">.</offsets></p></sec><sec><title><offsets xml_i="23785" xml_f="23862" txt_i="17698" txt_f="17775">Variations in the activities of key enzymes involved in antioxidative actions</offsets></title><p><offsets xml_i="23873" xml_f="23918" txt_i="17776" txt_f="17821">The activity of SOD decreased significantly (</offsets><italic><offsets xml_i="23926" xml_f="23927" txt_i="17821" txt_f="17822">p</offsets></italic><offsets xml_i="23936" xml_f="24054" txt_i="17822" txt_f="17937">&lt;0.0001, extremely significant) in preeclamptics not taking vitamins, whereas the decrease was simply significant (</offsets><italic><offsets xml_i="24062" xml_f="24063" txt_i="17937" txt_f="17938">p</offsets></italic><offsets xml_i="24072" xml_f="24145" txt_i="17938" txt_f="18011"> = 0.002) for those taking vitamins. There was a significant difference (</offsets><italic><offsets xml_i="24153" xml_f="24154" txt_i="18011" txt_f="18012">p</offsets></italic><offsets xml_i="24163" xml_f="24205" txt_i="18012" txt_f="18054"> = 0.0434) between these two Groups (Fig. </offsets><xref ref-type="fig" rid="F8"><offsets xml_i="24235" xml_f="24236" txt_i="18054" txt_f="18055">8</offsets></xref><offsets xml_i="24243" xml_f="24342" txt_i="18055" txt_f="18154">). Comparison of the activity of GPx in all the three Groups revealed no significant changes (Fig. </offsets><xref ref-type="fig" rid="F9"><offsets xml_i="24372" xml_f="24373" txt_i="18154" txt_f="18155">9</offsets></xref><offsets xml_i="24380" xml_f="24480" txt_i="18155" txt_f="18255">). But, interesting alterations were found in the activities of GRx, which decreased significantly (</offsets><italic><offsets xml_i="24488" xml_f="24489" txt_i="18255" txt_f="18256">p</offsets></italic><offsets xml_i="24498" xml_f="24699" txt_i="18256" txt_f="18457"> = 0.0138) in preeclamptics not having used vitamins. Those who consumed vitamin E and C during the gestational period from the second trimester of pregnancy to delivery demonstrated an insignificant (</offsets><italic><offsets xml_i="24707" xml_f="24708" txt_i="18457" txt_f="18458">p</offsets></italic><offsets xml_i="24717" xml_f="24751" txt_i="18458" txt_f="18492"> = 0.5395) fall in GRx activities.</offsets></p><p><offsets xml_i="24758" xml_f="24824" txt_i="18493" txt_f="18559">However, comparisons between Groups A and B showed a significant (</offsets><italic><offsets xml_i="24832" xml_f="24833" txt_i="18559" txt_f="18560">p</offsets></italic><offsets xml_i="24842" xml_f="24886" txt_i="18560" txt_f="18604"> = 0.05) difference in GRx activities (Fig. </offsets><xref ref-type="fig" rid="F10"><offsets xml_i="24917" xml_f="24919" txt_i="18604" txt_f="18606">10</offsets></xref><offsets xml_i="24926" xml_f="25063" txt_i="18606" txt_f="18743">). Catalase activities were elevated in both Groups A and B as compared to placebo, and the increase was found to be highly significant (</offsets><italic><offsets xml_i="25071" xml_f="25072" txt_i="18743" txt_f="18744">p</offsets></italic><offsets xml_i="25081" xml_f="25095" txt_i="18744" txt_f="18758"> = 0.0084 and </offsets><italic><offsets xml_i="25103" xml_f="25104" txt_i="18758" txt_f="18759">p</offsets></italic><offsets xml_i="25113" xml_f="25188" txt_i="18759" txt_f="18834"> = 0.0066, respectively), whereas no statistically significant difference (</offsets><italic><offsets xml_i="25196" xml_f="25197" txt_i="18834" txt_f="18835">p</offsets></italic><offsets xml_i="25206" xml_f="25274" txt_i="18835" txt_f="18903"> = 0.8555) was observed between Groups A and B, as depicted in Fig. </offsets><xref ref-type="fig" rid="F11"><offsets xml_i="25305" xml_f="25307" txt_i="18903" txt_f="18905">11</offsets></xref><offsets xml_i="25314" xml_f="25315" txt_i="18905" txt_f="18906">.</offsets></p></sec></sec><sec sec-type="discussion"><title><offsets xml_i="25365" xml_f="25375" txt_i="18909" txt_f="18919">Discussion</offsets></title><sec><title><offsets xml_i="25395" xml_f="25419" txt_i="18920" txt_f="18944">NO, MDA and NO/MDA ratio</offsets></title><p><offsets xml_i="25430" xml_f="25648" txt_i="18945" txt_f="19163">NO plays an important role in the pathogenesis of PE as the enhanced level of oxidative stress associated with the conditions increases the concentration of superoxide that reacts with NO to produce peroxynitrite (ONOO</offsets><sup><offsets xml_i="25653" xml_f="25654" txt_i="19163" txt_f="19164">−</offsets></sup><offsets xml_i="25660" xml_f="25960" txt_i="19164" txt_f="19464">), reducing the level of available NO. Peroxynitrite is a potentially harmful ROS as it causes nitrosylation of tyrosine residues, leading to changes in protein conformation and inactivation. Preeclampsia is associated with increased nitrotyrosine residues in placental villous vascular endothelium [</offsets><xref ref-type="bibr" rid="B40"><offsets xml_i="25992" xml_f="25994" txt_i="19464" txt_f="19466">40</offsets></xref><offsets xml_i="26001" xml_f="26375" txt_i="19466" txt_f="19840">]. The effect of elevation in peroxynitrite and reduced bioavailability of NO, resulting from enhanced production of free radicals and the resultant placental oxidative state, may contribute to the elevation of maternal blood pressure, proteinuria, platelet dysfunction and alteration in the level of thromboxane, prostacyclin and endothelin characteristic of preeclampsia [</offsets><xref ref-type="bibr" rid="B41"><offsets xml_i="26407" xml_f="26409" txt_i="19840" txt_f="19842">41</offsets></xref><offsets xml_i="26416" xml_f="26753" txt_i="19842" txt_f="20179">]. Another common source of placental oxidative damage is the peroxidation of membrane phospholipids that exerts a variety of effects within placenta. Our results on NO contents showed an increase of about 23–25% in preeclamptics, but the bioavailability of NO might have been blocked, as there was an increase of 29–36% in MDA contents.</offsets></p><p><offsets xml_i="26760" xml_f="27115" txt_i="20180" txt_f="20535">The oxidative destruction of polyunsaturated fatty acids (PUFAs) of phospholipids, known as lipid peroxidation, can be in fact considered as a hallmark of oxidative stress. PUFAs are important for the normal function of most of the cells. MDA, an end product of lipid peroxidation induced by ROS, is well correlated with the degree of lipid peroxidation [</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="27147" xml_f="27149" txt_i="20535" txt_f="20537">28</offsets></xref><offsets xml_i="27156" xml_f="27158" txt_i="20537" txt_f="20539">, </offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="27190" xml_f="27192" txt_i="20539" txt_f="20541">29</offsets></xref><offsets xml_i="27199" xml_f="27454" txt_i="20541" txt_f="20796">]. The result mentioned above revealed a highly significant increase in MDA content in preeclamptic patients in comparison to normal placebo. This may result in a greater potential for endothelial damage ultimately leading to elevated diastolic pressure [</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="27486" xml_f="27488" txt_i="20796" txt_f="20798">19</offsets></xref><offsets xml_i="27495" xml_f="27789" txt_i="20798" txt_f="21092">]. Enhanced ROS in turn can oxidize many other important biomolecules including erythrocyte membrane phospholipids. Thus, lipid peroxides and free radicals may be important in the pathogenesis of preeclampsia. Our results on MDA contents were consistent with the observations of other workers [</offsets><xref ref-type="bibr" rid="B31"><offsets xml_i="27821" xml_f="27823" txt_i="21092" txt_f="21094">31</offsets></xref><offsets xml_i="27830" xml_f="27832" txt_i="21094" txt_f="21096">, </offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="27864" xml_f="27866" txt_i="21096" txt_f="21098">19</offsets></xref><offsets xml_i="27873" xml_f="28233" txt_i="21098" txt_f="21458">] as well. The increase in MDA content in patients who took vitamin (group B) was simply significant (29%) when compared to group A in which it was very significant (36%). This shows the effectiveness of vitamins C and E in restricting the elevation of lipid peroxidation. Our results on NO contents were in agreement with the findings of other investigators [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="28265" xml_f="28267" txt_i="21458" txt_f="21460">20</offsets></xref><offsets xml_i="28274" xml_f="28276" txt_i="21460" txt_f="21462">, </offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="28308" xml_f="28310" txt_i="21462" txt_f="21464">21</offsets></xref><offsets xml_i="28317" xml_f="28676" txt_i="21464" txt_f="21823">]. Although levels of NO in preeclamptics, both without and with vitamin had increased significantly and highly significantly, respectively, there was no distinct improvement in blood pressure symptoms for either group. This shows that bioavailability of NO was restricted, perhaps due to its enhanced reaction with superoxide resulting in peroxynitrite (ONOO</offsets><sup><offsets xml_i="28681" xml_f="28682" txt_i="21823" txt_f="21824">−</offsets></sup><offsets xml_i="28688" xml_f="28709" txt_i="21824" txt_f="21845">) as mentioned above.</offsets></p><p><offsets xml_i="28716" xml_f="28786" txt_i="21846" txt_f="21916">The pathogenic link of serum uric acid is evident from other studies [</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="28818" xml_f="28820" txt_i="21916" txt_f="21918">25</offsets></xref><offsets xml_i="28827" xml_f="28829" txt_i="21918" txt_f="21920">, </offsets><xref ref-type="bibr" rid="B26"><offsets xml_i="28861" xml_f="28863" txt_i="21920" txt_f="21922">26</offsets></xref><offsets xml_i="28870" xml_f="29022" txt_i="21922" txt_f="22074">] and our results are consistent with their reports as the increase in uric acid contents in both groups A and B were found to be extremely significant.</offsets></p></sec><sec><title><offsets xml_i="29044" xml_f="29069" txt_i="22076" txt_f="22101">GSH, GSSG, GSSG/GSH ratio</offsets></title><p><offsets xml_i="29080" xml_f="29493" txt_i="22102" txt_f="22515">Glutathione and glutathione related enzymes are one of the major antioxidant systems within body. GSH is the most abundant thiol-based antioxidant, and is found primarily in the reduced form, with intracellular concentration up to 11 mM and provides sulfhydryl-buffering capacity. It also conveys an antioxidant power through the direct inactivation of ROS or by acting as an electron donor for GPx that reduces H</offsets><sub><offsets xml_i="29498" xml_f="29499" txt_i="22515" txt_f="22516">2</offsets></sub><offsets xml_i="29505" xml_f="29506" txt_i="22516" txt_f="22517">O</offsets><sub><offsets xml_i="29511" xml_f="29512" txt_i="22517" txt_f="22518">2</offsets></sub><offsets xml_i="29518" xml_f="29529" txt_i="22518" txt_f="22529"> to water [</offsets><xref ref-type="bibr" rid="B42"><offsets xml_i="29561" xml_f="29563" txt_i="22529" txt_f="22531">42</offsets></xref><offsets xml_i="29570" xml_f="29739" txt_i="22531" txt_f="22700">]. It has been suggested that the high levels of GSH may act as a compensatory mechanism in preeclampsia to prevent excessive lipid peroxidation via membrane bound GPx [</offsets><xref ref-type="bibr" rid="B43"><offsets xml_i="29771" xml_f="29773" txt_i="22700" txt_f="22702">43</offsets></xref><offsets xml_i="29780" xml_f="30290" txt_i="22702" txt_f="23212">]. In our study the erythrocyte GSSG concentration was very significantly elevated in preeclamptics, and we observed a significant increase in the redox potential values for the pair GSSG/GSH as compared to placebo, showing altered antioxidant balance. Our data clearly indicate that GSH in red blood cells decreased profoundly in preeclamptic pathophysiological conditions with a parallel increase in MDA and GSSG concentration. Our findings on MDA, GSH and GSSG are in agreement with those reported earlier [</offsets><xref ref-type="bibr" rid="B44"><offsets xml_i="30322" xml_f="30324" txt_i="23212" txt_f="23214">44</offsets></xref><offsets xml_i="30331" xml_f="30333" txt_i="23214" txt_f="23216">].</offsets></p></sec><sec><title><offsets xml_i="30355" xml_f="30381" txt_i="23218" txt_f="23244">SOD, GPx, catalase and GRx</offsets></title><p><xref ref-type="bibr" rid="B45"><offsets xml_i="30424" xml_f="30426" txt_i="23245" txt_f="23247">45</offsets></xref><offsets xml_i="30433" xml_f="30879" txt_i="23247" txt_f="23693">]. Deficient SOD activity may also increase oxidative insult by promoting the interaction of NO and superoxide to produce peroxynitrite as mentioned earlier. Superoxide dismutase and nitric oxide compete for superoxide. A consequence of SOD deficiency is an increase in nitric oxide interactions with superoxide, which results in the generation of peroxynitrite, subsequently reducing vasodilation through the impairment of NO and increasing ONOO</offsets><sup><offsets xml_i="30884" xml_f="30885" txt_i="23693" txt_f="23694">−</offsets></sup><offsets xml_i="30891" xml_f="30920" txt_i="23694" txt_f="23723"> induced lipid peroxidation [</offsets><xref ref-type="bibr" rid="B41"><offsets xml_i="30952" xml_f="30954" txt_i="23723" txt_f="23725">41</offsets></xref><offsets xml_i="30961" xml_f="31359" txt_i="23725" txt_f="24123">]. Our results on SOD activity clearly indicate an extremely significant decline (23%) in its activity in preeclamptic patients (Group A) and a significant decrease (14%) in preeclamptics using vitamin (Group B); a significant difference was observed between these two Groups (10–11%). From our results we infer the positive effect of vitamins C and E on retaining SOD activity during preeclampsia.</offsets></p><p><offsets xml_i="31366" xml_f="31691" txt_i="24124" txt_f="24449">The principal function of GPx is to protect against damage from the endogenously produced hydroxyperoxides and to catalyze the reduction of hydroxyperoxides by glutathione. Catalase promotes the conversion of hydrogen peroxide, a powerful and potentially harmful oxidizing agent, to water and molecular oxygen. It also uses H</offsets><sub><offsets xml_i="31696" xml_f="31697" txt_i="24449" txt_f="24450">2</offsets></sub><offsets xml_i="31703" xml_f="31704" txt_i="24450" txt_f="24451">O</offsets><sub><offsets xml_i="31709" xml_f="31710" txt_i="24451" txt_f="24452">2</offsets></sub><offsets xml_i="31716" xml_f="32728" txt_i="24452" txt_f="25464"> to oxidize toxins such as phenols, formic acid, formaldehyde and alcohols. Catalase, along-with SOD and GPx, controls the levels of oxygen-derived free radicals in cells. Our results show non-significant alterations in GPx activities. The activity of catalase increased very significantly in both Groups A and B (27% and 29% increase respectively), which shows its compensatory regulation in response to increased oxidative stress. No effect of vitamins C and E, however, was observed on GPx levels. GRx activity declined significantly (27%) in preeclamptics who had not consumed vitamins C and E (Group A), but its activity did not fall significantly (5.5%) in patients who had used these vitamins regularly as mentioned above. A comparison of these two Groups revealed a significant difference (22–29%), which shows that vitamins C and E consumption prevented the fall in GRx activity. This finding shows a clear correlation with the levels of GSH, which is evident from our results on GSH, GSSG and GSSG/GSH.</offsets></p><p><offsets xml_i="32735" xml_f="33570" txt_i="25465" txt_f="26300">In conclusion, we hypothesize enhanced oxidative stress in preeclampsia, on the basis of our results showing decreased SOD, GRx and GPx activities, with resulting inefficient control of the higher levels of oxygen free radicals produced. The increased activity of catalase that we observed may be a compensatory regulation in response to increased oxidative stress. Increased catalase activity could be interpreted as a futile effort to counteract the overproduction of reactive oxygen species, and to provide a relief to enhanced oxidative damage in preeclampsia. Lipid peroxides could participate in the cytotoxic mechanism leading to endothelial injury and enhanced blood pressure. The decreased concentration of glutathione supports the hypothesis that lipid peroxidation is an important factor in the pathogenesis of PE. Chappell </offsets><italic><offsets xml_i="33578" xml_f="33584" txt_i="26300" txt_f="26306">et al.</offsets></italic><offsets xml_i="33593" xml_f="33595" txt_i="26306" txt_f="26308"> [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="33626" xml_f="33627" txt_i="26308" txt_f="26309">1</offsets></xref><offsets xml_i="33634" xml_f="33928" txt_i="26309" txt_f="26603">] have reported that a significant reduction in the incidence of preeclampsia was found in women at risk who were taking a vitamins C and E supplements. They inferred a correlation between the PAI-1/PAI-2 (plasminogen activator inhibitor) ratio with vitamins C and E levels. Furthermore, they [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="33959" xml_f="33960" txt_i="26603" txt_f="26604">2</offsets></xref><offsets xml_i="33967" xml_f="34131" txt_i="26604" txt_f="26768">] suggested that antioxidant supplementation in women who were at risk of preeclampsia was associated with improvement in biochemical indices of the disease. Zhang </offsets><italic><offsets xml_i="34139" xml_f="34145" txt_i="26768" txt_f="26774">et al.</offsets></italic><offsets xml_i="34154" xml_f="34156" txt_i="26774" txt_f="26776"> [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="34187" xml_f="34188" txt_i="26776" txt_f="26777">7</offsets></xref><offsets xml_i="34195" xml_f="34337" txt_i="26777" txt_f="26919">] have reported a 2-fold increased risk of developing preeclampsia in women taking lower vitamin C doses. Several reports reviewed by Rodrigo </offsets><italic><offsets xml_i="34345" xml_f="34352" txt_i="26919" txt_f="26926">et al. </offsets></italic><offsets xml_i="34361" xml_f="34362" txt_i="26926" txt_f="26927">[</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="34393" xml_f="34394" txt_i="26927" txt_f="26928">9</offsets></xref><offsets xml_i="34401" xml_f="34465" txt_i="26928" txt_f="26992">] suggest the prophylactic use of vitamins C and E before the 20</offsets><sup><offsets xml_i="34470" xml_f="34472" txt_i="26992" txt_f="26994">th</offsets></sup><offsets xml_i="34478" xml_f="34661" txt_i="26994" txt_f="27177">. week of gestation, after identifying the risk factors on the basis of history of the patient, what would lower the risk of maternal vascular dysfunction and therein the onset of PE.</offsets></p><p><offsets xml_i="34668" xml_f="35858" txt_i="27178" txt_f="28368">We found that the patients supplemented with vitamin C 1000 mg plus vitamin E 400 IU daily from the second trimester of pregnancy until delivery showed improvements in certain biochemical indices during the development of preeclampsia. The elevation in MDA content was found to be significantly lower. Oxidation of reduced glutathione to GSSG was inhibited to a greater extent. The activities of antioxidant enzymes were also influenced by the use of vitamins C and E. The reduction of SOD activity during the development of preeclampsia was controlled as a consequence of vitamin consumption: the decrease was found to be 14% whereas it was 23% in patients who had not used vitamins C and E. The most prominent effect of the use of these vitamins was found to be associated with the activity of glutathione reductase. Reduction in its activity was much higher 27% as compared to that in patients who were taking vitamins (5.5%). Thus, we conclude that use of vitamins C and E definitely controls certain important biochemical indices during the development of preeclampsia, and that further studies are needed to develop strategies for the prevention of preeclampsia in women at high risk.</offsets></p></sec></sec></body><back><ack><title>Acknowledgments</title><p>We are highly grateful to those patients of our hospital who volunteered to donate their blood when needed for this project. The authors would also like to thank the paramedical staff of this hospital for their assistance in collecting and maintaining blood samples.</p></ack><glossary><title>Abbreviations</title><gloss-group><def-list><def-item><term>BMI</term><def><p>body mass index</p></def></def-item><def-item><term>U</term><def><p>unit</p></def></def-item><def-item><term>IU</term><def><p>international unit</p></def></def-item><def-item><term>Hb</term><def><p>hemoglobin</p></def></def-item><def-item><term>MDA</term><def><p>malondialdehyde</p></def></def-item><def-item><term>NO</term><def><p>nitric oxide</p></def></def-item><def-item><term>ATP</term><def><p>adenosine triphosphate</p></def></def-item><def-item><term>NADPH</term><def><p>nicotinamide adenine dinucleoltide phosphate reduced</p></def></def-item><def-item><term>FAD</term><def><p>flavin adenine dinucleotide</p></def></def-item><def-item><term>GSH</term><def><p>reduced glutathione</p></def></def-item><def-item><term>GSSG</term><def><p>oxidized glutathione</p></def></def-item><def-item><term>EDTA</term><def><p>Ethylene Diamine Tetra Acetic acid</p></def></def-item><def-item><term> TBA</term><def><p>thiobarbituric acid</p></def></def-item><def-item><term>BHT</term><def><p>butylated hydroxytoluene</p></def></def-item></def-list></gloss-group></glossary><ref-list><title>References</title><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chappell</surname><given-names>L.C.</given-names></name></person-group><article-title>Effect of antioxidants on the occurrence of preeclampsia in women at increased risk: a randomized trial</article-title><source>Lancet</source><volume>254</volume><fpage>810</fpage><lpage>816</lpage><year>1999</year><pub-id pub-id-type="pmid">10485722</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chappell</surname><given-names>L.C.</given-names></name></person-group><article-title>Vitamin C and E supplementation in women at risk of preeclampsia is associated with changes in indices of oxidative stress and placental function</article-title><source>Am. J. Obstet. Gynecol.</source><volume>187</volume><fpage>777</fpage><lpage>784</lpage><year>2002b</year><pub-id pub-id-type="pmid">12237663</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mohindra</surname><given-names>A.</given-names></name></person-group><article-title>Vitamin E and carotenes status in preeclamptic pregnant women from India</article-title><source>Panminerva Med.</source><volume>44</volume><fpage>261</fpage><lpage>264</lpage><year>2002</year><pub-id pub-id-type="pmid">12094143</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Panburana</surname><given-names>P.</given-names></name></person-group><article-title>Antioxidants nutrients and lipid peroxide levels in Thai preeclamptic women</article-title><source>J. Obstet. Gynaecol. Res.</source><volume>26</volume><fpage>377</fpage><lpage>381</lpage><year>2000</year><pub-id pub-id-type="pmid">11147727</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Llurba</surname><given-names>E.</given-names></name></person-group><article-title>A comprehensive study of oxidative stress and antioxidant status in preeclampsia and normal pregnancy</article-title><source>Free Radic. Biol. Med.</source><volume>37</volume><fpage>557</fpage><lpage>570</lpage><year>2004</year><pub-id pub-id-type="pmid">15256227</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chappell</surname><given-names>L.C.</given-names></name></person-group><article-title>A longitudinal study of biochemical variables in women at risk of preeclampsia</article-title><source>Am. J. Obstet. Gynecol.</source><volume>187</volume><fpage>127</fpage><lpage>136</lpage><year>2002a</year><pub-id pub-id-type="pmid">12114900</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C.</given-names></name></person-group><article-title>Vitamin C and the risk of preeclampsia-results from dietary questionnaire and plasma assay</article-title><source>Epidemiology</source><volume>13</volume><fpage>409</fpage><lpage>416</lpage><year>2002</year><pub-id pub-id-type="pmid">12094095</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Poston</surname><given-names>L.</given-names></name></person-group><article-title>Vitamin C and vitamin E in pregnant women at risk for preeclampsia (VIP trial): randomized placebo-controlled trial</article-title><source>Lancet</source><volume>367</volume><fpage>1145</fpage><lpage>1154</lpage><year>2006</year><pub-id pub-id-type="pmid">16616557</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rodrigo</surname><given-names>R.</given-names></name></person-group><article-title>Pathophysiological basis for the prophylaxis of preeclampsia through early supplementation with antioxidant</article-title><source>Pharmacol. Ther.</source><volume>107</volume><fpage>177</fpage><lpage>197</lpage><year>2005</year><pub-id pub-id-type="pmid">15896847</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>El-Salahy</surname><given-names>E.M.</given-names></name></person-group><article-title>New scope in angiogenesis: role of vascular endothelial growth factors (VEGF), NO, lipid peroxidation and vitamin E in the pathophysiology of the preeclampsia among Egyptian females</article-title><source>Clin. Biochem.</source><volume>34</volume><fpage>323</fpage><lpage>329</lpage><year>2001</year><pub-id pub-id-type="pmid">11440734</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akyol</surname><given-names>D.</given-names></name></person-group><article-title>Maternal levels of vitamin E in normal and preeclamptic pregnancy</article-title><source>Arch. Gynecol. Obstet.</source><volume>263</volume><fpage>151</fpage><lpage>155</lpage><year>2000</year><pub-id pub-id-type="pmid">10834320</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Madazli</surname><given-names>R.</given-names></name></person-group><article-title>Lipid peroxidation and antioxidant in preeclampsia</article-title><source>Eur. J. Obstet. Gynecol. Reprod. Biol.</source><volume>85</volume><fpage>205</fpage><lpage>208</lpage><year>1999</year><pub-id pub-id-type="pmid">10584636</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ben-Haroush</surname><given-names>A.</given-names></name></person-group><article-title>Plasma levels of vitamin E in pregnant women prior to the development of preeclampsia and hypertensive complications</article-title><source>Gynecol. Obstet. Invest.</source><volume>54</volume><fpage>26</fpage><lpage>30</lpage><year>2002</year><pub-id pub-id-type="pmid">12297714</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C.</given-names></name></person-group><article-title>Plasma concentrations of carotenoids, retinal, tocopherols in preeclamptic and normotensive pregnant women</article-title><source>Am. J. Epidemiol.</source><volume>153</volume><fpage>572</fpage><lpage>580</lpage><year>2001</year><pub-id pub-id-type="pmid">11257065</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mutlu</surname><given-names>T.U.</given-names></name></person-group><article-title>Plasma nitric oxide metabolites and lipid peroxide levels in preeclamptic pregnant women before and after delivery</article-title><source>Gynecol. Obstet. Invest.</source><volume>48</volume><fpage>247</fpage><lpage>250</lpage><year>1999</year><pub-id pub-id-type="pmid">10592426</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Norris</surname><given-names>L.A.</given-names></name></person-group><article-title>Nitric oxide in the uteroplacental, fetoplacental and peripheral circulation in preeclampsia</article-title><source>Obstet. Gynecol.</source><volume>93</volume><fpage>958</fpage><lpage>963</lpage><year>1999</year><pub-id pub-id-type="pmid">10362162</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kubes</surname><given-names>P.</given-names></name></person-group><article-title>Nitric oxide: an endogenous modulator of leukocyte adhesion</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>88</volume><fpage>4651</fpage><lpage>4655</lpage><year>1991</year><pub-id pub-id-type="pmid">1675786</pub-id></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Radomski</surname><given-names>M.W.</given-names></name></person-group><article-title>The antiaggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide</article-title><source>Br. J. Pharmacol.</source><volume>92</volume><fpage>639</fpage><lpage>646</lpage><year>1987</year><pub-id pub-id-type="pmid">3322462</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aydin</surname><given-names>A.</given-names></name></person-group><article-title>Plasma malondialdehyde, superoxide dismutase, sE-selectin, fibronectin, endothelin-1 and nitric oxide levels in women with preeclampsia</article-title><source>Eur. J. Obstet. Gynecol. Reprod. Biol.</source><volume>113</volume><fpage>21</fpage><lpage>25</lpage><year>2004</year><pub-id pub-id-type="pmid">15036705</pub-id></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shaamash</surname><given-names>A.H.</given-names></name></person-group><article-title>Maternal and fetal nitric oxide (NO) concentrations in normal pregnancy, preeclampsia and eclampsia</article-title><source>Int. J. Gynecol. Obstet.</source><volume>68</volume><fpage>207</fpage><lpage>214</lpage><year>2000</year></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smarason</surname><given-names>A.K.</given-names></name></person-group><article-title>Elevated levels of serum nitrate, a stable end product of nitric oxide in women with preeclampsia</article-title><source>Br. J. Obstet. Gynecol.</source><volume>104</volume><fpage>538</fpage><lpage>543</lpage><year>1997</year></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>J.W.</given-names></name></person-group><article-title>Nitric oxide production increases during normal pregnancy and decreases in preeclampsia</article-title><source>Ann. Clin. Lab. Sci.</source><volume>32</volume><fpage>257</fpage><lpage>263</lpage><year>2002</year><pub-id pub-id-type="pmid">12175088</pub-id></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davidge</surname><given-names>S.T.</given-names></name></person-group><article-title>Urine but not plasma nitric oxide metabolites are decreased in women with preeclampsia</article-title><source>Am. J. Obstet. Gynecol.</source><volume>174</volume><fpage>1008</fpage><lpage>1013</lpage><year>1996</year><pub-id pub-id-type="pmid">8633627</pub-id></citation></ref><ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diejomaoh</surname><given-names>F.M.</given-names></name></person-group><article-title>Nitric oxide production is not altered in preeclampsia</article-title><source>Arch. Gynecol. Obstet.</source><volume>269</volume><fpage>237</fpage><lpage>243</lpage><year>2004</year><pub-id pub-id-type="pmid">15221318</pub-id></citation></ref><ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>J.M.</given-names></name></person-group><article-title>Uric acid is as important as proteinuria in identifying fetal risk in women with gestational hypertension</article-title><source>Hypertension</source><volume>46</volume><fpage>1263</fpage><lpage>1269</lpage><year>2005</year><pub-id pub-id-type="pmid">16246973</pub-id></citation></ref><ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>D’Anna</surname><given-names>R.</given-names></name></person-group><article-title>The clinical utility of serum uric acid measurements in preeclampsia and transient hypertension in pregnancy</article-title><source>Panminerva Med.</source><volume>42</volume><fpage>101</fpage><lpage>103</lpage><year>2000</year><pub-id pub-id-type="pmid">10965770</pub-id></citation></ref><ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>R.J.</given-names></name></person-group><article-title>Is there a pathogenic role for uric acid in hypertension and cardiovascular and renal disease</article-title><source>Hypertension</source><volume>41</volume><fpage>1183</fpage><lpage>1190</lpage><year>2003</year><pub-id pub-id-type="pmid">12707287</pub-id></citation></ref><ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hubel</surname><given-names>C.A.</given-names></name></person-group><article-title>Lipid peroxidation in pregnancy: new perspectives on preeclampsia</article-title><source>Am. J. Obstet. Gynecol.</source><volume>161</volume><fpage>1025</fpage><lpage>1034</lpage><year>1989</year><pub-id pub-id-type="pmid">2679100</pub-id></citation></ref><ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vanderlelie</surname><given-names>J.</given-names></name></person-group><article-title>Increased biological oxidation and reduced anti-oxidant enzyme activity in pre-eclamptic placentae</article-title><source>Placenta</source><volume>26</volume><fpage>53</fpage><lpage>58</lpage><year>2005</year><pub-id pub-id-type="pmid">15664411</pub-id></citation></ref><ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>Reduced cellular glutathione reductase activity and increased adhesion molecule expression in endothelial cells cultured with plasma of women with preeclampsia</article-title><source>J. Soc. Gynecol. Investig.</source><volume>13</volume><fpage>412</fpage><lpage>417</lpage><year>2006</year></citation></ref><ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Atamer</surname><given-names>Y.</given-names></name></person-group><article-title>Lipid peroxidation, antioxidant defense, status of trace metals and leptin levels in preeclampsia</article-title><source>Eur. J. Obstet. Gynecol. Biol.</source><volume>119</volume><fpage>60</fpage><lpage>66</lpage><year>2005</year></citation></ref><ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buchanan</surname><given-names>M.J.</given-names></name></person-group><article-title>Serum Uric Acid Estimation. Chemical and enzymatic methods compared</article-title><source>Ann. Rheum. Dis.</source><volume>25</volume><fpage>285</fpage><lpage>288</lpage><year>1965</year><pub-id pub-id-type="pmid">14297344</pub-id></citation></ref><ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tentori</surname><given-names>L.</given-names></name></person-group><article-title>Hemoglobinometry in human blood</article-title><source>Methods Enzymol.</source><volume>76</volume><fpage>707</fpage><lpage>715</lpage><year>1981</year><pub-id pub-id-type="pmid">7329285</pub-id></citation></ref><ref id="B34"><label>34</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Beutler</surname><given-names>E.</given-names></name></person-group><source>Red Cell Metabolism, A Manual of Biochemical Methods. 3rd, ed</source><publisher-name>Grune and Stratton Inc.</publisher-name><publisher-loc>New York</publisher-loc><year>1984</year></citation></ref><ref id="B35"><label>35</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Videla</surname><given-names>L.A.</given-names></name></person-group><source>Metabolism of hepatic glutathione. Laboratory exercise I. 1-6, In: Oxygen radicals in Biochemistry, biophysics and medicine. International training course. School of Pharmacy and Biochemistry</source><publisher-name>Buenos Aires, University of Buenos Aires</publisher-name><publisher-loc>Argentina</publisher-loc><volume>7</volume><comment>-18.3,</comment><year>1994</year></citation></ref><ref id="B36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>S.K.</given-names></name></person-group><article-title>Erythrocyte membrane lipid peroxidation and glycosylated hemoglobin in diabetes</article-title><source>Diabetes</source><volume>38</volume><fpage>1539</fpage><lpage>1543</lpage><year>1989</year><pub-id pub-id-type="pmid">2583378</pub-id></citation></ref><ref id="B37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paglia</surname><given-names>D.E.</given-names></name></person-group><article-title>Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase</article-title><source>J. Lab. Clin. Med.</source><volume>70</volume><fpage>158</fpage><lpage>169</lpage><year>1967</year><pub-id pub-id-type="pmid">6066618</pub-id></citation></ref><ref id="B38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aebi</surname><given-names>H.</given-names></name></person-group><article-title>Catalase <italic>in vitro</italic></article-title><source>Methods Enzymol.</source><volume>105</volume><fpage>121</fpage><lpage>126</lpage><year>1984</year><pub-id pub-id-type="pmid">6727660</pub-id></citation></ref><ref id="B39"><label>39</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>D.M.</given-names></name></person-group><source>Glutathione reductase, in Methods Enzymol</source><person-group person-group-type="editor"><name><surname>Bergmeyer</surname><given-names>H.U.</given-names></name></person-group><publisher-name>Verlag Chemie</publisher-name><publisher-loc>Basel</publisher-loc><volume>3</volume><fpage>258</fpage><lpage>265</lpage><year>1983</year></citation></ref><ref id="B40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>R.H.</given-names></name></person-group><article-title>Essential role of p38alpha MAP kinase in placental but not embryonic cardiovascular development</article-title><source>Molecular Cell</source><volume>6</volume><fpage>109</fpage><lpage>116</lpage><year>2000</year><pub-id pub-id-type="pmid">10949032</pub-id></citation></ref><ref id="B41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lowe</surname><given-names>D.T.</given-names></name></person-group><article-title>Nitric oxide dysfunction in the pathophysiology of preeclampsia</article-title><source>Nitric Oxide</source><volume>4</volume><fpage>441</fpage><lpage>458</lpage><year>2000</year><pub-id pub-id-type="pmid">10944429</pub-id></citation></ref><ref id="B42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>H.</given-names></name></person-group><article-title>Biological significance of phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx<sub>4</sub>) in mammalian cells</article-title><source>Free Radic. Bio. Med.</source><volume>34</volume><fpage>145</fpage><lpage>169</lpage><year>2003</year><pub-id pub-id-type="pmid">12521597</pub-id></citation></ref><ref id="B43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knapen</surname><given-names>M.F.</given-names></name></person-group><article-title>Glutathione and glutathione related enzymes in deciduas and placenta of controls and women with preeclampsia</article-title><source>Placenta</source><volume>20</volume><fpage>541</fpage><lpage>546</lpage><year>1999</year><pub-id pub-id-type="pmid">10452907</pub-id></citation></ref><ref id="B44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Padmini</surname><given-names>E.</given-names></name></person-group><article-title>Placental heat shock protein 70 overexpression confers resistance against oxidative stress in preeclampsia</article-title><source>Turk J. Med. Sci.</source><volume>38</volume><fpage>27</fpage><lpage>34</lpage><year>2008</year></citation></ref><ref id="B45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liochev</surname><given-names>S.I.</given-names></name></person-group><article-title>How does superoxide dismutase protect against tumor necrosis factor: a hypothesis informed by effect of superoxide on “free” iron</article-title><source>Free Radic. Biol. Med.</source><volume>23</volume><fpage>668</fpage><lpage>671</lpage><year>1997</year><pub-id pub-id-type="pmid">9215812</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="F1" position="float"><label>Fig. 1</label><caption><p>MDA contents. Columns show mean values. Vertical bars represent SEM.</p><p>P = 6.22 ± 2.8 (SEM = 0.6261) A = 8.48 ± 1.2 (SEM = 0.2558) B = 8.02 ± 1.8 (SEM = 0.3928) Values are Mean ± SD.</p><p>Group A- PE without Vit. Supplements compared to placebo-P (Difference highly significant, <italic>p</italic> = 0.0013);</p><p>Group B- PE with Vit. Supplements compared to placebo-P (Difference significant, <italic>p</italic> = 0.0184);</p><p>Group A compared to Group B (Difference not significant, <italic>p</italic> = 0.3278).</p></caption><graphic xlink:href="jcbn2008067f01"></graphic></fig><fig id="F2" position="float"><label>Fig. 2</label><caption><p>Nitric oxide contents. Columns show mean values. Vertical bars represent SEM.</p><p>P = 19.3 ± 4.2 (SEM = 0.939) A = 23.8 ± 6.4 (SEM = 1.364) B = 24.1 ± 5.4 (SEM = 1.178) Values are mean ± SD.</p><p>Group A- PE without Vit. Supplements compared to placebo-P (Difference significant, <italic>p</italic> = 0.0111);</p><p>Group B- PE with Vit. Supplements compared to placebo-P (Difference highly significant, <italic>p</italic> = 0.003);</p><p>Group A compared to Group B (Difference not significant,<italic> p</italic> = 0.8692).</p></caption><graphic xlink:href="jcbn2008067f02"></graphic></fig><fig id="F3" position="float"><label>Fig. 3</label><caption><p>Ratio of NO/MDA. Columns show mean values. Vertical bars represent SEM.</p><p>P = 3.103 ± 0.8 (SEM = 0.1789) A = 2.807 ± 0.6 (SEM = 0.1279) B = 3.005 ± 0.5 (SEM = 0.1091) Values are mean ± SD.</p><p>Group A- PE without Vit. Supplements compared to placebo-P (Difference not significant, <italic>p</italic> = 0.18);</p><p>Group B- PE with Vit. Supplements compared to placebo-P (Difference not significant, <italic>p</italic> = 0.6389);</p><p>Group A compared to Group B (Difference not significant,<italic> p</italic> = 0.2477).</p></caption><graphic xlink:href="jcbn2008067f03"></graphic></fig><fig id="F4" position="float"><label>Fig. 4</label><caption><p>Reduced glutathione contents. Columns show mean values. Vertical bars represent SEM.</p><p>P = 10.42 ± 2.81 (SEM = 0.6283) A = 8.02 ± 2.92 (SEM = 0.6225) B = 9.39 ± 1.02 (SEM = 0.2226) Values are mean ± SD.</p><p>Group A- PE without Vit. Supplements compared to placebo-P (Difference highly significant, <italic>p</italic> = 0.0099);</p><p>Group B- PE with Vit. Supplements compared to placebo-P (Difference not significant, <italic>p</italic> = 0.1233);</p><p>Group A compared to Group B (Difference significant, <italic>p</italic> = 0.0485).</p></caption><graphic xlink:href="jcbn2008067f04"></graphic></fig><fig id="F5" position="float"><label>Fig. 5</label><caption><p></p><p>P = 0.98 ± 0.28 (SEM = 0.0626) A = 1.24 ± 0.29 (SEM = 0.0618) B = 1.08 ± 0.12 (SEM = 0.0262). Values are mean ± SD.</p><p>Group A- PE without Vit. Supplements compared to placebo-P (Difference highly significant, <italic>p</italic> = 0.0053);</p><p>Group B- PE with Vit. Supplements compared to placebo-P (Difference not significant, <italic>p</italic> = 0.1419);</p><p>Group A compared to Group B (Difference significant,<italic> p</italic> = 0.0241).</p></caption><graphic xlink:href="jcbn2008067f05"></graphic></fig><fig id="F6" position="float"><label>Fig. 6</label><caption><p>Ratio of GSSG/GSH in three groups. Columns show mean values. Vertical bars represent SEM.</p><p>P = 0.0941 ± 0.08 (SEM = 0.01789) A = 0.155 ± 0.04 (SEM = 0.00853) B = 0.115 ± 0.06 (SEM = 0.01309) Values are mean ± SD.</p><p>Group A- PE without Vit. Supplements compared to placebo-P (Difference highly significant, <italic>p</italic> = 0.003);</p><p>Group B- PE with Vit. Supplements compared to placebo-P (Difference not significant, <italic>p</italic> = 0.3483);</p><p>Group A compared to Group B (Difference significant, <italic>p</italic> = 0.0134).</p></caption><graphic xlink:href="jcbn2008067f06"></graphic></fig><fig id="F7" position="float"><label>Fig. 7</label><caption><p>Uric acid contents. Columns show mean values. Vertical bars represent SEM.</p><p>P = 6.5 ± 1.02 (SEM = 0.2281) A = 9.2 ± 1.84 (SEM = 0.3923) B = 8.5 ± 1.51 (SEM = 0.3295). Values are Mean ± SD.</p><p>Group A- PE without Vit. Supplements compared to placebo-P (Difference extremely significant, <italic>p</italic>&lt;0.0001);</p><p>Group B- PE with Vit. Supplements compared to placebo-P (Difference extremely significant,<italic> p</italic>&lt;0.0001);</p><p>Group A compared to Group B (Difference not significant, <italic>p</italic> = 0.1813).</p></caption><graphic xlink:href="jcbn2008067f07"></graphic></fig><fig id="F8" position="float"><label>Fig. 8</label><caption><p>Superoxide dismutase activities. Columns show mean values. Vertical bars represent SEM.</p><p>P = 710 ± 90.6 (SEM = 20.259) A = 548 ± 92.8 (SEM = 19.785) B = 610 ± 102.2 (SEM = 22.302). Values are Mean ± SD.</p><p>Group A- PE without Vit. Supplements compared to placebo-P (Difference extremely significant,<italic> p</italic>&lt;0.0001);</p><p>Group B- PE with Vit. Supplements compared to placebo-P (Difference highly significant, <italic>p</italic> = 0.002);</p><p>Group A compared to Group B (Difference significant, <italic>p</italic> = 0.0434).</p></caption><graphic xlink:href="jcbn2008067f08"></graphic></fig><fig id="F9" position="float"><label>Fig. 9</label><caption><p>Glutathione peroxidase activities. Columns show mean values. Vertical bars represent SEM.</p><p>P = 14.6 ± 3.8 (SEM = 0.85) A = 12.8 ± 3.2 (SEM = 0.682) B = 13.2 ± 4.8 (SEM = 1.047). Values are Mean ± SD.</p><p>Group A- PE without Vit. Supplements compared to placebo-P (Difference not significant, <italic>p</italic> = 0.1036);</p><p>Group B- PE with Vit. Supplements compared to placebo-P (Difference not significant, <italic>p</italic> = 0.3084);</p><p>Group A compared to Group B (Difference not significant, <italic>p</italic> = 0.7484).</p></caption><graphic xlink:href="jcbn2008067f09"></graphic></fig><fig id="F10" position="float"><label>Fig. 10</label><caption><p>Glutathione reductase activities. Columns show mean values. Vertical bars represent SEM.</p><p>P = 11.2 ± 3.08 (SEM = 0.6887) A = 8.22 ± 4.26 (SEM = 0.9082) B = 10.58 ± 3.32 (SEM = 0.7245). Vales are Mean ± SD.</p><p>Group A- PE without Vit. Supplements compared to placebo-P (Difference significant, <italic>p</italic> = 0.0138);</p><p>Group B- PE with Vit. Supplements compared to placebo-P (Difference not significant, <italic>p</italic> = 0.5395);</p><p>Group A compared to Group B (Difference significant, <italic>p</italic> = 0.05).</p></caption><graphic xlink:href="jcbn2008067f10"></graphic></fig><fig id="F11" position="float"><label>Fig. 11</label><caption><p>Catalase activities. Columns show mean values. Vertical bars represent SEM.</p><p>P = 98.2 ± 30.4 (SEM = 6.798) A = 124.8 ± 31.6 (SEM = 6.737) B = 126.6 ± 32.8 (SEM = 7.158). Values are Mean ± SD.</p><p>Group A- PE without Vit. Supplements compared to placebo-P (Difference highly significant, <italic>p</italic> = 0.0084);</p><p>Group B- PE with Vit. Supplements compared to placebo-P (Difference highly significant <italic>p</italic> = 0.0066);</p><p>Group A compared to Group B (Difference not significant, <italic>p</italic> = 0.8555).</p></caption><graphic xlink:href="jcbn2008067f11"></graphic></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Demographic and clinical characteristics of three study groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Parameters</th><th align="center" valign="middle" rowspan="1" colspan="1">Control (Placebo) (<italic>n</italic> = 20)</th><th align="center" rowspan="1" colspan="1">Preeclamptics (PE) without vitamin supplements Group A (<italic>n</italic> = 22)</th><th align="center" rowspan="1" colspan="1">Preeclamptics (PE) with vitamin supplements Group B (<italic>n</italic> = 21)</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic> values (two tailed probability)</th><th align="center" valign="middle" rowspan="1" colspan="1">Statistical significance</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (year)</td><td align="center" rowspan="1" colspan="1">28.8 ± 7.2</td><td align="center" rowspan="1" colspan="1">29.2 ± 6.4</td><td align="center" rowspan="1" colspan="1">27.4 ± 8.4</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">—</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean gestational age at sampling (weeks)</td><td align="center" rowspan="1" colspan="1">36.4 ± 1.8</td><td align="center" rowspan="1" colspan="1">34.4 ± 2.2</td><td align="center" rowspan="1" colspan="1">33.8 ± 2.4</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">—</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI at sampling weight/(height)2 Kg/(m)2</td><td align="center" rowspan="1" colspan="1">21.8 ± 3.4</td><td align="center" rowspan="1" colspan="1">19.3 ± 1.8</td><td align="center" rowspan="1" colspan="1">20.2 ± 2.6</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">—</td></tr><tr><td rowspan="2" align="left" colspan="1">Systolic BP (mmHg)</td><td align="center" rowspan="1" colspan="1">109.4 ± 8.8</td><td align="center" rowspan="1" colspan="1">158 ± 14.6</td><td align="center" rowspan="1" colspan="1">152 ± 12.4</td><td align="center" rowspan="1" colspan="1">&lt;0.000<sup>a</sup></td><td align="left" rowspan="1" colspan="1">(extremely significant)</td></tr><tr><td align="center" rowspan="1" colspan="1">(SEM = 1.968)</td><td align="center" rowspan="1" colspan="1">(SEM = 3.113)</td><td align="center" rowspan="1" colspan="1">(SEM = 2.706)</td><td align="center" rowspan="1" colspan="1">&lt;0.0001<sup>b</sup></td><td align="left" rowspan="1" colspan="1">(extremely significant)</td></tr><tr><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1">0.1549<sup>c</sup></td><td align="left" rowspan="1" colspan="1">(not significant)</td></tr><tr><td rowspan="2" align="left" colspan="1">Diastolic BP (mmHg)</td><td align="center" rowspan="1" colspan="1">66 ± 8.2</td><td align="center" rowspan="1" colspan="1">110.4 ± 4.2</td><td align="center" rowspan="1" colspan="1">103.8 ± 16.8</td><td align="center" rowspan="1" colspan="1">&lt;0.0001<sup>a</sup></td><td align="left" rowspan="1" colspan="1">(extremely significant)</td></tr><tr><td align="center" rowspan="1" colspan="1">(SEM = 1.834)</td><td align="center" rowspan="1" colspan="1">(SEM = 0.895)</td><td align="center" rowspan="1" colspan="1">(SEM = 3.666)</td><td align="center" rowspan="1" colspan="1">&lt;0.0001<sup>b</sup></td><td align="left" rowspan="1" colspan="1">(extremely significant)</td></tr><tr><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1">0.0815<sup>c</sup></td><td align="left" rowspan="1" colspan="1">(not significant)</td></tr><tr><td rowspan="2" align="left" colspan="1">Pulse rate (beats/min)</td><td align="center" rowspan="1" colspan="1">70.6 ± 2.8</td><td align="center" rowspan="1" colspan="1">72.6 ± 3.8</td><td align="center" rowspan="1" colspan="1">70.4 ± 3.6</td><td align="center" rowspan="1" colspan="1">0.0613<sup>a</sup></td><td align="left" rowspan="1" colspan="1">(not significant)</td></tr><tr><td align="center" rowspan="1" colspan="1">(SEM = 0.626)</td><td align="center" rowspan="1" colspan="1">(SEM = 0.810)</td><td align="center" rowspan="1" colspan="1">(SEM = 0.786)</td><td align="center" rowspan="1" colspan="1">0.8442<sup>b</sup></td><td align="left" rowspan="1" colspan="1">(not significant)</td></tr><tr><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1">0.0584<sup>c</sup></td><td align="left" rowspan="1" colspan="1">(not significant)</td></tr><tr><td align="left" rowspan="1" colspan="1">Proteinuria (gm/day)</td><td align="center" rowspan="1" colspan="1">Nil</td><td align="center" rowspan="1" colspan="1">1.78 ± 0.6</td><td align="center" rowspan="1" colspan="1">0.8 ± 0.4</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">—</td></tr><tr><td align="left" rowspan="1" colspan="1">Edema</td><td align="center" rowspan="1" colspan="1">Nil</td><td align="center" rowspan="1" colspan="1">++ in all cases</td><td align="center" rowspan="1" colspan="1">++ in all cases</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">—</td></tr></tbody></table><table-wrap-foot><p>Values are expressed as mean ± SD <italic>n</italic> = number of subjects studied. <sup>a</sup> (Group A compared to placebo); <sup>b</sup> (Group B compared to placebo ); <sup>c</sup> ( Group A compared to Group B).</p></table-wrap-foot></table-wrap></floats-wrap></article>